Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT02658968 | Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | completed | Phase 1 | 18 | Nordic NanovectorINDUSTRY | 5 | Jan 16, 2024 | clinicaltrials |
| NCT03833180 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | completed | Phase 1 | 91 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT01606878 | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 | 46 | Children's Oncology GroupNETWORK | 2 | Jan 5, 2024 | clinicaltrials |
| NCT02697344 | Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | completed | Phase 1 | 10 | Mayo ClinicOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT04439006 | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | completed | Phase 1 | 10 | Jennifer WoyachOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03806179 | Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL(LYMRIT-37-07) | completed | Phase 1 | 7 | Nordic NanovectorINDUSTRY | 2 | Dec 22, 2023 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT02561273 | Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 54 | University of NebraskaOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT01421524 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | completed | Phase 1 | 271 | CelgeneINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT04121260 | A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma | completed | Phase 1 | 21 | Janssen Research & Development, LLCINDUSTRY | 1 | Dec 8, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT00697684 | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant | completed | Phase 1 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03072771 | Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 1 | 14 | Washington University School of MedicineOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04812691 | CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma | completed | Phase 1 | 12 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02543879 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 94 | Forma Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT00047060 | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | completed | Phase 1 / Phase 2 | 5 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00924170 | Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03274219 | Study of bb21217 in Multiple Myeloma | completed | Phase 1 | 72 | 2seventy bioINDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02728531 | Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT02206425 | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02417285 | A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. | completed | Phase 1 | 75 | CelgeneINDUSTRY | 3 | Oct 23, 2023 | clinicaltrials |
| NCT02916979 | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG(FluBuATG) | completed | Phase 1 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT03188965 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 | 229 | BayerINDUSTRY | 7 | Oct 11, 2023 | clinicaltrials |
| NCT01035463 | Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 74 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02509052 | Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 12 | City of Hope Medical CenterOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02611323 | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 1 / Phase 2 | 133 | Hoffmann-La RocheINDUSTRY | 3 | Oct 10, 2023 | clinicaltrials |
| NCT02685826 | A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 56 | CelgeneINDUSTRY | 8 | Oct 6, 2023 | clinicaltrials |
| NCT03605719 | Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 23 | Emory UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01060384 | Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 46 | University of NebraskaOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT01301807 | Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT00571493 | VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 42 | University of NebraskaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03571308 | A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)(ACCEPT) | completed | Phase 1 / Phase 2 | 39 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00550615 | Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 38 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03309878 | Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01336920 | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | Phase 1 | 15 | University of NebraskaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05917964 | A Food Effect Study of LP-168 Tablets in Healthy Subjects | completed | Phase 1 | 22 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 11, 2023 | clinicaltrials |
| NCT03338972 | Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT03733717 | Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 25 | SanofiINDUSTRY | 1 | Sep 8, 2023 | clinicaltrials |
| NCT05176873 | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants | completed | Phase 1 | 64 | Dizal (Jiangsu) Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT04196491 | A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)(KarMMa-4) | completed | Phase 1 | 13 | CelgeneINDUSTRY | 1 | Aug 23, 2023 | clinicaltrials |
| NCT04445701 | Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 10 | Arch OncologyINDUSTRY | 1 | Aug 22, 2023 | clinicaltrials |
| NCT01484093 | Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 96 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT02514382 | Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 14 | University of Southern CaliforniaOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03010358 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 24 | Alexey Danilov, MDOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT00443976 | Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 35 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01614197 | A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | completed | Phase 1 | 16 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Jul 27, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2024source: clinicaltrials